NCT07164703尚未招募不适用
Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital
Mao-Lin Yan1 个研究点 分布在 1 个国家目标入组 55 人开始时间: 2025年10月1日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 55
- 试验地点
- 1
- 主要终点
- Objective response rate, ORR
研究概览
简要总结
This is a multi-center, real-world study aiming to evaluate the efficacy and safety of precision treatment for advanced cholangiocarcinoma (CCA) with different molecular subtypes.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 and ≤ 75 years.
- •Histologically confirmed, unresectable advanced biliary tract carcinoma, including cholangiocarcinoma (intrahepatic or extrahepatic) and gallbladder cancer (diagnosed according to the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines for Biliary Tract Malignancies and confirmed by a multidisciplinary team). Must have a documented targetable gene mutation, including but not limited to: Fibroblast Growth Factor Receptor 2 (FGFR2) fusion/rearrangement, Isocitrate Dehydrogenase (NADP(+)) 1 (IDH-1) and Isocitrate Dehydrogenase (NADP(+)) 2 (IDH-2) mutations, Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2/HER2) amplification and/or overexpression, B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) V600E mutation, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) mutation, Neurotrophic Tyrosine Receptor Kinase (NTRK) fusion, Rearranged during Transfection (RET) fusion, Ring Finger Protein 43 (RNF43) mutation, MET Proto-Oncogene, Receptor Tyrosine Kinase (MET) amplification, Epidermal Growth Factor Receptor (EGFR) mutation, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) mutation, BRCA1 DNA Repair Associated (BRCA1)/BRCA2 DNA Repair Associated (BRCA2) mutation, Partner and Localizer of BRCA2 (PALB2) mutation, Vascular Endothelial Growth Factor Receptor (VEGFR) mutation, deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H), or Neuregulin 1 (NRG1) mutation.
- •At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (measurable lesion defined as longest diameter ≥10 mm on Computed Tomography (CT)/Magnetic Resonance Imaging (MRI) scan).
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Child-Pugh class A or B liver function. For patients with obstructive jaundice, total bilirubin must be ≤ 50 µmol/L. Biliary drainage is recommended if total bilirubin is > 50 µmol/L.
- •Adequate hematologic function: Absolute Neutrophil Count (ANC) ≥ 1.5 × 10^9/L, Hemoglobin (Hb) ≥ 8.5 g/L, Platelets (PLT) ≥ 75 × 10^9/L.
- •No history of severe arrhythmia or heart failure; no severe ventilation dysfunction or severe pulmonary infection; no acute or chronic renal failure with creatinine clearance > 40 mL/min.
- •Life expectancy of more than 3 months.
排除标准
- •Major surgery within 28 days prior to enrollment.
- •Presence of any unresolved toxicity of Grade ≥ 2 (according to Common Terminology Criteria for Adverse Events [CTCAE] v4.0) from prior anticancer therapy at the time of enrollment, with the exception of alopecia or Grade 2 anemia.
- •Known hypersensitivity to any components or excipients of the study drugs.
- •Presence of any active autoimmune disease or a history of autoimmune disease with an expected recurrence. Patients currently receiving immunosuppressants or systemic corticosteroids for immunosuppressive purposes.
- •Presence of other concurrent malignancies.
- •Presence of brain metastases or spinal cord compression.
- •Presence of any severe and/or unstable pre-existing medical conditions, mental illness, or other conditions that could compromise patient safety, the ability to provide informed consent, or adherence to the study procedures.
- •Pregnant or breastfeeding women.
- •History of organ transplantation.
- •Patients with proteinuria ≥ 1+ on urinalysis must undergo a 24-hour urine protein test. Patients with a 24-hour urine protein level ≥ 1g are excluded.
- •Clinically significant corneal or retinal disease confirmed by ophthalmologic examination.
- •Liver tumor burden exceeding 50%.
- •Hypothyroidism or hyperthyroidism.
研究组 & 干预措施
Precision Treatment Based on Molecular Subtyping (or Gene Mutations)
干预措施: Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations. (Drug)
结局指标
主要结局
Objective response rate, ORR
时间窗: Four weeks after the initiation of medication
The Objective response rate (ORR) was defined as the complete response (CR) rate or the partial response (PR) rate according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
次要结局
- Treatment-related adverse events, TRAEs treatment-related adverse events(From the initiation of medication, with recordings made whenever an adverse reaction occurs, assessed up to 48 months)
- Conversion Resection Rate, CRR(Four weeks after the initiation of medication until the day before surgery)
- Overall survival, OS(From date of enrollment until the date of death from any cause, assessed up to 48 months)
- Disease control rate, DCR(Four weeks after the initiation of medication)
- Progression-free survival, PFS(From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months)
研究者
Mao-Lin Yan
Principal Investigator
Fujian Provincial Hospital
研究点 (1)
Loading locations...
相似试验
招募中
不适用
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICCIntrahepatic CholangiocarcinomaNCT06643208Fujian Provincial Hospital37
已完成
不适用
Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)Pancreatic CancerNCT06947395Immunovia, Inc.386
已完成
不适用
PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and AlgorithmDiabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT03251079Senseonics, Inc.36
尚未招募
不适用
AbdominaL and Lung Point-of-Care UltraSound for Tuberculosis in Germany and IndiaCTRI/2021/03/032094German Infectious Disease Research Center DZIF770
招募中
不适用
Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOXPancreas AdenocarcinomaPancreas MetastasesPancreas CancerNCT06349278Laval University15